Last reviewed · How we verify
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone is a Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved.
At a glance
| Generic name | Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone CI brief — competitive landscape report
- Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI
Frequently asked questions about Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
What is Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone?
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone is a Small molecule drug developed by Peking Union Medical College Hospital.
Who makes Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone?
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone is developed and marketed by Peking Union Medical College Hospital (see full Peking Union Medical College Hospital pipeline at /company/peking-union-medical-college-hospital).
What development phase is Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone in?
Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone is FDA-approved (marketed).